XNAS · Healthcare · Biotechnology
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.28 | -0.34 | -21.43% | $169,000 | ❌ Miss | +1.71% | -18.28% | — |
| 2026-03-31 | Q4 2025 | -0.30 | -0.27 | +10.00% | $0 | ✅ Beat | +5.34% | +7.63% | -5.73% |
| 2025-11-12 |
| Q3 2025 |
| -0.27 |
| -0.31 |
| -14.81% |
| $16,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.22 | -0.23 | -4.55% | $48,000 | ❌ Miss | +8.81% | -29.24% | -33.90% |
| 2025-03-31 | FY 2024 | — | -0.28 | — | $26.0M | — | +4.04% | +9.11% | +49.38% |
| 2024-09-05 | H1 2024 | — | 0.14 | — | $24.1M | — | +5.05% | +0.85% | +5.89% |
| 2024-04-16 | FY 2023 | — | -1.08 | — | $0 | — | -10.40% | -19.65% | -0.58% |
| 2023-09-12 | H1 2023 | — | -0.50 | — | $0 | — | +2.93% | -5.34% | +16.13% |
Showing last 8 quarters.